Word: fda
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
With its eye on cost, the Food and Drug Administration last week took testimony on whether to require makers of the blockbuster allergy drugs Claritin, Allegra and Zyrtec to sell the products over the counter, a move that would slash their prices. An FDA advisory panel ruled that the drugs were safe enough to be sold without prescription. While the FDA is not required to follow the panel's advice, it has usually done so. A switch to over-the-counter sales would benefit uninsured buyers--as well as insurers, such as the California managed-care giant WellPoint Health Networks...
...Folkman of Children's Hospital in Boston, launched thousands of research studies. But the concept of antiangiogenesis hasn't gone well lately. Major pharmaceutical firms have stopped work on their favorite antiangiogenesis candidates, and not one of the 50 other compounds under study has yet been approved by the FDA--despite three decades of research and an investment of some $4 billion...
...next few months, these recommendations will be compiled by the Angiogenesis Foundation, a nonprofit clearinghouse for research in the field, and forwarded to the FDA and the National Institutes of Health, which funds the bulk of cancer research...
When officials at the FDA take just 2 1/2 months to approve a new cancer treatment, you know it's got to be some kind of breakthrough. And indeed the drug called Gleevec, which was given the go-ahead last week in record time, has produced dramatic results in patients with a rare malignancy called chronic myeloid leukemia. It's too early to say just how good Gleevec is. But the drug's success so far makes one thing clear. When designing a safe, effective treatment for a particular cancer, it pays to learn as much as possible about...
...pinning higher hopes to T-20, which is entering Phase Three - the final stage of development. "We've been using T-20 for at least a year in clinical trials," Dr. Joel Gallant, director of the Moore AIDS Clinic at the Johns Hopkins University Medical Center, told TIME.com. The FDA will begin deliberating on the drug sometime this year, Dr. Gallant adds, and will likely consider the drug on an accelerated approval schedule. "I don't think we'll see it approved in this calendar year, although we may see improved access to the drug in certain areas," he says...